Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/98484
Title: Advances in mammalian cell line development technologies for recombinant protein production
Authors: Lai, Tingfeng
Yang, Yuansheng
Ng, Say Kong
Keywords: DRNTU::Science::Medicine::Pharmacy::Pharmaceutical technology
Issue Date: 2013
Source: Lai, T., Yang, Y., & Ng, S. K. (2013). Advances in mammalian cell line development technologies for recombinant protein production. Pharmaceuticals, 6(5), 579-603.
Series/Report no.: Pharmaceuticals
Abstract: From 2006 to 2011, an average of 15 novel recombinant protein therapeutics have been approved by US Food and Drug Administration (FDA) annually. In addition, the expiration of blockbuster biologics has also spurred the emergence of biosimilars. The increasing numbers of innovator biologic products and biosimilars have thus fuelled the demand of production cell lines with high productivity. Currently, mammalian cell line development technologies used by most biopharmaceutical companies are based on either the methotrexate (MTX) amplification technology or the glutamine synthetase (GS) system. With both systems, the cell clones obtained are highly heterogeneous, as a result of random genome integration by the gene of interest and the gene amplification process. Consequently, large numbers of cell clones have to be screened to identify rare stable high producer cell clones. As such, the cell line development process typically requires 6 to 12 months and is a time, capital and labour intensive process. This article reviews established advances in protein expression and clone screening which are the core technologies in mammalian cell line development. Advancements in these component technologies are vital to improve the speed and efficiency of generating robust and highly productive cell line for large scale production of protein therapeutics.
URI: https://hdl.handle.net/10356/98484
http://hdl.handle.net/10220/18419
ISSN: 1424-8247
DOI: 10.3390/ph6050579
Rights: © 2013 The Authors (published by MDPI). This paper was published in Pharmaceuticals and is made available as an electronic reprint (preprint) with permission of the authors. The paper can be found at the following official DOI: [http://dx.doi.org/10.3390/ph6050579]. One print or electronic copy may be made for personal use only. Systematic or multiple reproduction, distribution to multiple locations via electronic or other means, duplication of any material in this paper for a fee or for commercial purposes, or modification of the content of the paper is prohibited and is subject to penalties under law.
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:SCBE Journal Articles

SCOPUSTM   
Citations 1

196
Updated on Dec 3, 2022

Web of ScienceTM
Citations 1

180
Updated on Nov 30, 2022

Page view(s) 50

502
Updated on Dec 6, 2022

Download(s) 5

430
Updated on Dec 6, 2022

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.